CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-15 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 193,494 | ||
| 2023-11-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,500 | $35.40 | $89K | 150,664 |
| 2023-10-30 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 453,917 |
| 2023-10-30 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $32.17 | $402K | 441,417 |
| 2023-10-30 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 205,994 | ||
| 2023-10-16 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 453,917 |
| 2023-10-16 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $33.70 | $421K | 441,417 |
| 2023-10-16 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 218,494 | ||
| 2023-10-12 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,500 | $35.89 | $90K | 153,164 |
| 2023-10-06 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 453,917 |
| 2023-10-06 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $30.00 | $375K | 441,417 |
| 2023-10-06 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 230,994 | ||
| 2023-10-02 | Harrington Robert Arthur Director | Grant or award | +448 | $27.88 | $12K | 11,373 |
| 2023-10-02 | HENDERSON JOHN T Director | Grant or award | +762 | $27.88 | $21K | 31,818 |
| 2023-10-02 | Kaye Edward M. MD Director | Grant or award | +448 | $27.88 | $12K | 19,169 |
| 2023-10-02 | SMITH SANDFORD D Director | Grant or award | +448 | $27.88 | $12K | 18,653 |
| 2023-10-02 | WIERENGA WENDALL Director | Grant or award | +448 | $27.88 | $12K | 18,653 |
| 2023-10-02 | Wysenski Nancy Director | Grant or award | +224 | $27.88 | $6K | 17,082 |
| 2023-09-14 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,500 | $34.86 | $87K | 155,664 |
| 2023-09-13 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 453,917 |
Page 38 of 45 · 885 trades